Reuters logo
BRIEF-Capricor Therapeutics advances clinical development program in Duchenne muscular dystrophy
September 26, 2017 / 11:18 AM / 24 days ago

BRIEF-Capricor Therapeutics advances clinical development program in Duchenne muscular dystrophy

Sept 26 (Reuters) - Capricor Therapeutics Inc

* Capricor Therapeutics advances clinical development program in Duchenne muscular dystrophy with naming of principal investigator

* Capricor Therapeutics Inc - Capricor plans to commence enrollment in HOPE-2 trial in Q1 of 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below